New Clot-Busting device shows promise for lung blockages

NCT ID NCT05560763

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a device called the FlowTriever2 Catheter in 50 people with acute pulmonary embolism (blood clots in the lungs). The device was used to mechanically remove clots from the lung arteries. Researchers measured safety by tracking serious side effects and effectiveness by checking changes in lung artery pressure. The goal was to see if this approach could quickly improve blood flow and reduce harm from the clots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
FlowTriever2 Catheter (a device inserted into blood vessels to mechanically remove clots from the lung arteries)
What this could lead to
If successful, this device could offer a way to quickly reduce dangerous blood clots in the lungs, potentially improving blood flow and reducing complications.
What could go wrong
This was a small, single-arm study with only 50 participants, so results may not apply to everyone. There are risks of bleeding, vessel injury, or worsening symptoms during the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Baptist Health

    Louisville, Kentucky, 40207, United States

  • Carondelet St. Joseph's Hospital

    Tucson, Arizona, 85711, United States

  • Memorial Health University Medical Center

    Savannah, Georgia, 31404, United States

  • Oklahoma Heart Institute

    Tulsa, Oklahoma, 74104, United States

  • University of Tennessee Medical Center

    Knoxville, Tennessee, 37920, United States

  • Virtua Health

    Camden, New Jersey, 08103, United States

  • Yale University

    New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.